AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32175973 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 185
Study 32175973 — intervention group
Group type: EXPERIMENTAL
Intervention: All training groups combined (subgroup analysis)
Number of subjects: 185
Study 36191986 — intervention group
Group type: EXPERIMENTAL
Intervention: ICIs plus chemotherapy (chemoimmunotherapy)
Number of subjects: 103
Study 36191986 — intervention group
Group type: EXPERIMENTAL
Intervention: ICIs plus chemotherapy (chemoimmunotherapy) with prior brain radiotherapy
Number of subjects: 103
Study 36180164 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Practice
Number of subjects: 16
Study 36180164 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 34497852 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin adjunct to continuous subcutaneous insulin infusion (CSII)
Number of subjects: 66
Study 34497852 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 66
Study 33965556 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented training combined with aerobic training (TOT-AT)
Number of subjects: 40
Study 33965556 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 40
Study 32859666 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, face-to-face, individually tailored activity and exercise programme
Number of subjects: 0
Study 32859666 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in intervention delivery due to COVID-19
Number of subjects: 0
Study 32859666 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote support for therapy programme
Number of subjects: 0
Study 34749395 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin plus bendamustine and rituximab (pola + BR)
Number of subjects: 192
Study 34749395 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine and rituximab (BR)
Number of subjects: 192
Study 34749395 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) in extension cohort
Number of subjects: 192
Study 33792547 — intervention group
Group type: EXPERIMENTAL
Intervention: Slip Buddy app
Number of subjects: 64
Study 33792547 — intervention group
Group type: COMPARATOR
Intervention: Calorie tracking app
Number of subjects: 64
Study 33060179 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of biological motion (BM) actions by the CC group
Number of subjects: 0
Study 33060179 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent motion (CM) detection task by the CC group
Number of subjects: 0
Study 33060179 — intervention group
Group type: COMPARATOR
Intervention: Vision matched (VM) control group
Number of subjects: 0
Study 33060179 — intervention group
Group type: COMPARATOR
Intervention: Sighted control (SC) group
Number of subjects: 0
Study 33060179 — intervention group
Group type: COMPARATOR
Intervention: Developmental cataract (DC) reversal individuals (DC group)
Number of subjects: 0
Study 35572961 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-Thumbtack Needle (ETN) therapy administered three times a week for four consecutive weeks
Number of subjects: 180
Study 35572961 — intervention group
Group type: COMPARATOR
Intervention: Sham ETN therapy administered three times a week for four consecutive weeks
Number of subjects: 180
Study 35572961 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-Thumbtack Needle (ETN) therapy
Number of subjects: 180
Study 35572961 — intervention group
Group type: COMPARATOR
Intervention: Sham ETN therapy
Number of subjects: 180
Study 33214593 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Assembling Peptide P11‐4 (SAP P11‐4)
Number of subjects: 2
Study 33214593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SAP P11‐4 and delayed FV after 90 days
Number of subjects: 2
Study 33214593 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (FV)
Number of subjects: 2
Study 35783486 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimer 4571 adjuvanted with 500 mcg alum, administered subcutaneously or intramuscularly at weeks 0, 8, and 20 in doses of 100 mcg or 500 mcg
Number of subjects: 16
Study 32979986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fevipiprant 150 mg
Number of subjects: 1771
Study 32979986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fevipiprant 450 mg
Number of subjects: 1771
Study 32979986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1771
Study 32659437 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS PA Advisor
Number of subjects: 350
Study 32659437 — intervention group
Group type: COMPARATOR
Intervention: Telephone PA Advisor
Number of subjects: 350
Study 32659437 — intervention group
Group type: COMPARATOR
Intervention: SMS Nutrition Advisor
Number of subjects: 350
Study 34237271 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7049389 200 mg twice a day
Number of subjects: 37
Study 34237271 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7049389 400 mg twice a day
Number of subjects: 37
Study 34237271 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7049389 200 mg once a day
Number of subjects: 37
Study 34237271 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7049389 600 mg once a day
Number of subjects: 37
Study 34237271 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7049389 1000 mg once a day
Number of subjects: 37
Study 34237271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 35687059 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine bolus at 0.10 μg/kg
Number of subjects: 120
Study 35687059 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine bolus at 0.05 μg/kg
Number of subjects: 120
Study 32876804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (2000 mg/day)
Number of subjects: 39
Study 32876804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 33269511 — intervention group
Group type: COMPARATOR
Intervention: TRS-HFDM score 0
Number of subjects: 5123
Study 33269511 — intervention group
Group type: COMPARATOR
Intervention: TRS-HFDM score 1
Number of subjects: 5123
Study 33269511 — intervention group
Group type: COMPARATOR
Intervention: TRS-HFDM score 2
Number of subjects: 5123
Study 33269511 — intervention group
Group type: COMPARATOR
Intervention: TRS-HFDM score 3
Number of subjects: 5123
Study 33269511 — intervention group
Group type: COMPARATOR
Intervention: TRS-HFDM score 4+
Number of subjects: 5123
Study 33269511 — intervention group
Group type: COMPARATOR
Intervention: TRS-HFDM overall
Number of subjects: 5123
Study 33269511 — intervention group
Group type: COMPARATOR
Intervention: TRS-HFDM in participants without baseline HF
Number of subjects: 5123
Study 35904638 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation combined with enteral nutrition
Number of subjects: 108
Study 35904638 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing without enteral nutrition
Number of subjects: 108
Study 34844551 — intervention group
Group type: EXPERIMENTAL
Intervention: Secnidazole 2.0 g po followed by Azithromycin 500 mg on day 1 continuing by 250 mg on days 2-7
Number of subjects: 154
Study 34844551 — intervention group
Group type: EXPERIMENTAL
Intervention: Secnidazole 2.0 g po followed by Josamycin 1000 mg bid for 12 days
Number of subjects: 154
Study 34844551 — intervention group
Group type: EXPERIMENTAL
Intervention: Secnidazole 2.0 g po followed by Moxifloxacin 400 mg once daily for 12 days
Number of subjects: 154
Study 34047715 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-centered activity-based therapy (parent-supervised) in addition to institutional physiotherapy
Number of subjects: 59
Study 34047715 — intervention group
Group type: COMPARATOR
Intervention: Ongoing institutional physiotherapy alone
Number of subjects: 59
Study 33183345 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS with BCBT
Number of subjects: 130
Study 33183345 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS with BCBT
Number of subjects: 130
Study 35856722 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education regarding fasting recommendations (eat until 6 hours and drink until 2 hours before EGD)
Number of subjects: 109
Study 35856722 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 109
Study 33543507 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) rinse
Number of subjects: 69
Study 33543507 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 69
Study 32287316 — intervention group
Group type: EXPERIMENTAL
Intervention: P60.4Ac-containing ototopical drops (0.25-2.0 mg of peptide/ml)
Number of subjects: 34
Study 32287316 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 34
Study 35384460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined predictive model based on MR Rad-S and clinical risk factors
Number of subjects: 434
Study 35384460 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model
Number of subjects: 434
Study 35384460 — intervention group
Group type: COMPARATOR
Intervention: Radiomics model
Number of subjects: 434
Study 32853646 — intervention group
Group type: EXPERIMENTAL
Intervention: Water pressure (WP) method
Number of subjects: 0
Study 32853646 — intervention group
Group type: EXPERIMENTAL
Intervention: DualKnife J
Number of subjects: 0
Study 32853646 — intervention group
Group type: EXPERIMENTAL
Intervention: Late treatment phase
Number of subjects: 0
Study 32075185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed supervised/home‐based exercise program for six months
Number of subjects: 6
Study 32075185 — intervention group
Group type: COMPARATOR
Intervention: Control group without exercise
Number of subjects: 6
Study 34749577 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 33
Study 34749577 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Jump Training (PJT)
Number of subjects: 33
Study 34749577 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 33
Study 33159256 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mizoribine (MZR) pulse therapy combined with steroid treatment
Number of subjects: 60
Study 33159256 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment of steroid combined with cyclophosphamide (CPM)
Number of subjects: 60
Study 32853755 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training followed by neurofeedback sessions
Number of subjects: 32
Study 32853755 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving simulation-based training and neurofeedback)
Number of subjects: 32
Study 35882875 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible BIS group (depth of anaesthesia sustained between 40 and 60)
Number of subjects: 69
Study 35882875 — intervention group
Group type: COMPARATOR
Intervention: Hidden BIS group (depth of anaesthesia guided by hemodynamic parameters and Minimum Alveolar Concentration)
Number of subjects: 69
Study 35882875 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible BIS group
Number of subjects: 69
Study 35882875 — intervention group
Group type: COMPARATOR
Intervention: Hidden BIS group
Number of subjects: 69
Study 33763699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg plus lenalidomide and dexamethasone (Rd)
Number of subjects: 705
Study 33763699 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lenalidomide and dexamethasone (Rd)
Number of subjects: 705
Study 32862697 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 13885
Study 32862697 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 10 mmHg increase in SBP >125 mmHg
Number of subjects: 13885
Study 32862697 — intervention group
Group type: EXPERIMENTAL
Intervention: Every decrease in 10 mmHg SBP ≤125 mmHg
Number of subjects: 13885
Study 36106858 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Number of subjects: 33
Study 36106858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 34106753 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity hematopoietic cell transplantation (HCT) in the Donor arm
Number of subjects: 384
Study 34106753 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care or hypomethylating therapy in the No-Donor arm
Number of subjects: 384
Study 33508252 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-item Person-Centered Contraceptive Counseling scale (PCCC)
Number of subjects: 33
Study 33508252 — intervention group
Group type: COMPARATOR
Intervention: 11-item Interpersonal Quality of Family Planning (IQFP) scale
Number of subjects: 33
Study 32448171 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasis-directed therapy to all visible progressive lesions
Number of subjects: 18
Study 32448171 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA PET‐CT imaging
Number of subjects: 18
Study 36233540 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision™ Paediatric aBlade™ video laryngoscope (KVL)
Number of subjects: 11
Study 36233540 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 11
Study 33861742 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of traditional and religious leaders in intervention LGAs
Number of subjects: 2598
Study 33861742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training of traditional and religious leaders)
Number of subjects: 2598
Study 35604530 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 2
Study 35604530 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 2
Study 32682484 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, dexamethasone, and daratumumab (KdD)
Number of subjects: 466
Study 32682484 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 466
Study 34183429 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi (once-daily)
Number of subjects: 0
Study 34183429 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30 (twice-daily)
Number of subjects: 0
Study 34183429 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study 32408108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel protocols using senna (81.0%) and bisacodyl (75.6%) among others.
Number of subjects: 44
Study 32408108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel protocols activated by nurses (62.8%) based on initiation criteria.
Number of subjects: 44
Study 32408108 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxative escalation criteria.
Number of subjects: 44
Study 32408108 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation criteria for bowel protocols.
Number of subjects: 44
Study 36152128 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal exposure to arsenic
Number of subjects: 352
Study 36152128 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-exposure to arsenic and mercury
Number of subjects: 352
Study 32352642 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma retinol levels <58.3 μg/dL
Number of subjects: 1234
Study 32352642 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma retinol levels ≥58.3 μg/dL
Number of subjects: 1234
Study 32352642 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher time-averaged SBP (≥140 mm Hg) in participants with plasma retinol <58.3 μg/dL
Number of subjects: 1234
Study 32352642 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher vitamin E levels (≥11.5 μg/mL) in participants with plasma retinol <58.3 μg/dL
Number of subjects: 1234
Study 35880280 — intervention group
Group type: COMPARATOR
Intervention: Warm needling
Number of subjects: 90
Study 35880280 — intervention group
Group type: COMPARATOR
Intervention: Balance acupotomy
Number of subjects: 90
Study 35880280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (balance acupotomy + warm needling)
Number of subjects: 90
Study 34000503 — intervention group
Group type: EXPERIMENTAL
Intervention: Air cleaner devices (recirculating and filtering air)
Number of subjects: 2123
Study 34000503 — intervention group
Group type: COMPARATOR
Intervention: Normal air (control group)
Number of subjects: 2123
Study 32230987 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg twice daily in Week 1) followed by Inulin (4 g twice daily)
Number of subjects: 60
Study 32230987 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (twice daily in Week 1) followed by Inulin
Number of subjects: 60
Study 32230987 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Placebo
Number of subjects: 60
Study 33039185 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete dentures with palatal rugae
Number of subjects: 50
Study 33039185 — intervention group
Group type: COMPARATOR
Intervention: Complete dentures with polished palate
Number of subjects: 50
Study 33039185 — intervention group
Group type: EXPERIMENTAL
Intervention: OHIP-EDENT total scores with palatal rugae
Number of subjects: 50
Study 32931308 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (DPT)
Number of subjects: 32
Study 32931308 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 32
Study 34607479 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM group (74 patients)
Number of subjects: 105
Study 34607479 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnant group (31 women)
Number of subjects: 105
Study 33788480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (acupuncture, moxibustion, Chinese herbal medicine, and western medication)
Number of subjects: 60
Study 33788480 — intervention group
Group type: COMPARATOR
Intervention: Western medication group (clomiphene citrate, chorionic gonadotrophin, and aspirin)
Number of subjects: 60
Study 32780258 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Group (PG) received Lactobacillus acidophilus and Bifidobacterium lactis (5 billion CFU/strain) for 90 days
Number of subjects: 73
Study 32780258 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) received tablets with starch
Number of subjects: 73
Study 33455938 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal cytokine adsorption using the CytoSorb device
Number of subjects: 80
Study 33455938 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cytokine adsorption)
Number of subjects: 80
Study 32298270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Attention Focused Exercise (SAFEx), n = 18
Number of subjects: 35
Study 32298270 — intervention group
Group type: COMPARATOR
Intervention: Sham Exercise control (external focus of attention), n = 17
Number of subjects: 35
Study 36235570 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (8 g)
Number of subjects: 36
Study 36235570 — intervention group
Group type: COMPARATOR
Intervention: Soy protein (7.5 g)
Number of subjects: 36
Study 32822692 — intervention group
Group type: EXPERIMENTAL
Intervention: Early or late prenatal vitamin D sufficiency (25(OH)D level ≥ 30 ng/mL) among mothers with asthma
Number of subjects: 806
Study 32822692 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and late prenatal vitamin D sufficiency (25(OH)D level ≥ 30 ng/mL) among mothers with asthma
Number of subjects: 806
Study 32822692 — intervention group
Group type: EXPERIMENTAL
Intervention: Early or late prenatal vitamin D sufficiency (25(OH)D level ≥ 30 ng/mL)
Number of subjects: 806
Study 35811277 — intervention group
Group type: EXPERIMENTAL
Intervention: HFOV combined with prone position (HFOV-PP)
Number of subjects: 65
Study 35811277 — intervention group
Group type: COMPARATOR
Intervention: HFOV combined with supine position (HFOV-SP)
Number of subjects: 65
Study 34100099 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon guide catheter (BGC)
Number of subjects: 0
Study 34100099 — intervention group
Group type: COMPARATOR
Intervention: Conventional guide catheters
Number of subjects: 0
Study 32338067 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine max (L.) Merr isoflavone 4% vaginal gel
Number of subjects: 22
Study 32338067 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 22
Study 32338067 — intervention group
Group type: COMPARATOR
Intervention: Comparison between isoflavone and placebo groups
Number of subjects: 22
Study 34518253 — intervention group
Group type: EXPERIMENTAL
Intervention: selfBACK app adjunct to usual care
Number of subjects: 279
Study 34518253 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Help website adjunct to usual care
Number of subjects: 279
Study 34518253 — intervention group
Group type: COMPARATOR
Intervention: usual care only
Number of subjects: 279
Study 32160348 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance phase after low-energy diet
Number of subjects: 1856
Study 32160348 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and sociocognitive factors
Number of subjects: 1856
Study 35641010 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 986
Study 35641010 — intervention group
Group type: COMPARATOR
Intervention: Standard recommended treatment regimen of chronic stable heart failure
Number of subjects: 986
Study 32517739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency ablation (CRFA)
Number of subjects: 177
Study 32517739 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover cohort (HA to CRFA)
Number of subjects: 177
Study 32517739 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 177
Study 36083159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy visible (HEV) light-filtering contact lens
Number of subjects: 61
Study 36083159 — intervention group
Group type: COMPARATOR
Intervention: Clear comparison contact lens
Number of subjects: 61
Study 32298143 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer concussion-education program (PCEP)
Number of subjects: 1614
Study 35791797 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan (50 mg) based triple therapy (TPZ)
Number of subjects: 350
Study 35791797 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg) based triple therapy (LPZ)
Number of subjects: 350
Study 34374027 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR0302 4 mg once daily
Number of subjects: 105
Study 34374027 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR0302 8 mg once daily
Number of subjects: 105